Q-omics provides the consensus-scored KRT8P51 profile across patient tissues and cancer cell-line models. KRT8P51 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, KRT8P51 is differentially expressed in 9, with the highest sampling consensus in BRCA. Additionally, KRT8P51 RNA expression shows 12,804 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BRCA, and GBM as cancer lineages where KRT8P51 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT8P51 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT8P51 survival associations across molecular data types. KRT8P51 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT8P51 RNA expression–survival associations across cancer types. High KRT8P51 expression shows unfavorable associations in BRCA and PCPG, but favorable associations in HNSC, UCEC, READ and LUSC. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .006). Together, the overview and detailed table identify BRCA as the clearest survival context for KRT8P51 RNA expression.
This table summarizes KRT8P51 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for KRT8P51. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT8P51 shows lower tumor expression in BLCA and higher tumor expression in BRCA, KIRC, UCEC, HNSC and LUSC. The BRCA box plot shows higher KRT8P51 RNA expression in tumor versus normal tissue (log2 FC = +0.195, t-test p < 0.001).
This table shows molecular features associated with KRT8P51 in patient tissues and cancer cell lines. In patient samples, KRT8P51 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
